Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company focused on developing molecular glue degrader (MGD)-based medicines, has announced its participation in the Jefferies London Healthcare Conference. CEO Markus Warmuth will engage in a fireside chat on November 19, 2024, at 4:00 p.m. GMT. The presentation will be available through webcast in the 'Events' section of Monte Rosa's website, with recordings accessible for 30 days after the event.
Monte Rosa Therapeutics (Nasdaq: GLUE), una società biotech in fase clinica specializzata nello sviluppo di medicinali basati su degradatori a collante molecolare (MGD), ha annunciato la sua partecipazione alla Conferenza Sanitaria di Jefferies a Londra. Il CEO Markus Warmuth parteciperà a una chiacchierata informale il 19 novembre 2024 alle 16:00 GMT. La presentazione sarà disponibile in streaming nella sezione 'Eventi' del sito di Monte Rosa, con registrazioni accessibili per 30 giorni dopo l'evento.
Monte Rosa Therapeutics (Nasdaq: GLUE), una compañía biotecnológica en fase clínica centrada en el desarrollo de medicamentos basados en degradadores de pegamento molecular (MGD), ha anunciado su participación en la Conferencia de Salud de Jefferies en Londres. El CEO Markus Warmuth participará en una charla amena el 19 de noviembre de 2024 a las 4:00 p.m. GMT. La presentación estará disponible a través de un webcast en la sección 'Eventos' del sitio web de Monte Rosa, con grabaciones accesibles durante 30 días después del evento.
몬테 로사 테라퓨틱스 (나스닥: GLUE), 분자 접착 분해제(MGD) 기반 의약품 개발에 주력하는 임상 단계 생명공학 회사가 제퍼리즈 런던 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO 마르쿠스 바르무스는 2024년 11월 19일 오후 4시 GMT에 진행되는 대담에 참여합니다. 발표는 몬테 로사 웹사이트의 '이벤트' 섹션에서 웹캐스트를 통해 제공되며, 행사 후 30일 동안 녹화 영상을 시청할 수 있습니다.
Monte Rosa Therapeutics (Nasdaq: GLUE), une entreprise biopharmaceutique en phase clinique axée sur le développement de médecines basées sur des dégradateurs de colle moléculaire (MGD), a annoncé sa participation à la Conférence de Santé Jefferies à Londres. Le PDG Markus Warmuth participera à un entretien informel le 19 novembre 2024 à 16h00 GMT. La présentation sera disponible via un webcast dans la section 'Événements' du site Web de Monte Rosa, avec des enregistrements accessibles pendant 30 jours après l'événement.
Monte Rosa Therapeutics (Nasdaq: GLUE), ein biopharmazeutisches Unternehmen in klinischer Phase, das sich auf die Entwicklung von medikamentösen Lösungen basierend auf molekularen Kleberabbauern (MGD) spezialisiert hat, hat seine Teilnahme an der Jefferies London Healthcare Conference bekannt gegeben. CEO Markus Warmuth wird am 19. November 2024 um 16:00 Uhr GMT an einem informellen Gespräch teilnehmen. Die Präsentation wird über ein Webcast im Abschnitt 'Veranstaltungen' der Website von Monte Rosa verfügbar sein, und Aufzeichnungen werden für 30 Tage nach der Veranstaltung zugänglich sein.
- None.
- None.
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 4:00 p.m. GMT.
A webcast of the fireside chat will be accessible via the “Events” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. Monte Rosa has a global license agreement with Novartis to advance VAV1-directed molecular glue degraders and a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
When is Monte Rosa Therapeutics (GLUE) presenting at the Jefferies London Healthcare Conference 2024?
How can I watch Monte Rosa Therapeutics' (GLUE) presentation at the Jefferies Conference?
How long will Monte Rosa Therapeutics' (GLUE) Jefferies Conference presentation be available online?
What type of medicines does Monte Rosa Therapeutics (GLUE) develop?
